CLINICAL TRIAL OF AN ANTI-THYROXINE COMPOUND

Abstract

1. An anti-thyroxine compound, n-butyl-3:5-diiodo-4-hydroxy-benzoate (BDHB), did not exert any anti-thyroxine effect during the treatment of one myxoedematous patient with intravenous thyroxine. 2. This drug, when given for short periods to nine thyrotoxic patients, induced a partial remission, no greater than that obtained in two of these patients with iodides, and not well sustained beyond about three weeks' administration. 3. The results suggest that this drug cannot be employed clinically in dosages high enough to produce a definite anti-thyroxine effect.